Robert Bradway named president and COO at Amgen
This article was originally published in Scrip
Amgen has named Robert Bradway president and chief operating officer, effective 11 May. He will report to the company's chairman and CEO, Kevin Sharer, and will be responsible for global commercial operations, manufacturing operations, strategy & corporate development, IT, global government affairs and compliance. Mr Bradway has served as Amgen's executive vice-president and chief financial officer since April 2007, having joined the company in 2006 as vice-president of operations strategy. Before that, he was a managing director at Morgan Stanley in London, where he was responsible for the firm's banking department and corporate finance activities in Europe. Michael Kelly, Amgen's vice-president of finance and chief accounting officer, will serve as acting CFO, effective 11 May. He joined Amgen in 2003 and has served as chief accounting officer since 2005. Amgen also announced that its executive vice-president of global commercial operations, George Morrow, is to retire on 31 January 2011.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.